Brief: Resmed Q2 Adjusted EPS USD 2.43 Vs. IBES Estimate USD 2.31
30/01/2025 21:05
Jan 30 (Reuters) - Resmed Q2 adjusted gross margin 59.2%. * Q2 gross margin 58.6% * Q2 revenue USD 1,300 million vs. IBES estimate USD 1,268 million * Q2 EPS USD 2.34
Recent news on ResMed
See all newsCiti lifts ResMed's ASX-listed stock's target price after FX, valuation updates
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Brief: Resmed - Enters Accelerated Share Repurchase Agreement To Repurchase $450 Million Of Common Stock - SEC Filing
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT